GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$44.18M
MomentumView details →
1D Return
−1.87%
YTD Return
−39.60%
RSI (14)
41.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$44.18M
RSI (14)
41.5
MomentumView details →
1D Return
−1.87%
YTD Return
−39.60%
SummaryUpdated Jun 1, 2026
Grace Therapeutics, Inc. (NASDAQ:GRCE) is a clinical-stage biotechnology company focused on developing pharmaceutical treatments for rare and orphan diseases. Originally incorporated in 2002 as Acasti Pharma Inc., the company underwent a strategic transformation and rebranded to Grace Therapeutics in October 2024. Headquartered in Princeton, New Jersey, the company went public in February 2012 and has since pivoted from its original focus to concentrate on addressing unmet medical needs in rare disease populations where treatment options are limited or non-existent.
Similar companies
Latest newsMore news →
Grace Therapeutics announced its financial results for the first quarter of fiscal 2027 (three months ended June 30, 2026).23d agoGrace Therapeutics announced a $10 million private placement, with expected gross proceeds anticipated to extend the company's cash runway to the end of calendar 2028.31d agoGrace Therapeutics received Type A meeting minutes from the U.S. Food and Drug Administration regarding a Complete Response Letter for GTx-104.39d ago